Leadership Team

Joshua has a proven track record of building successful diagnostics companies. In 2013 he started ArcherDX, a leading genomics analysis company developing industry-leading products and services for therapy optimization and cancer monitoring. Throughout his tenure, Joshua held leadership roles with increasing responsibility before becoming Chief Scientific Officer and Chief Operating Officer. He helped build ArcherDX into a leading global diagnostic organization, which was the first to have a Next Generation Sequencing (NGS)-based liquid biopsy companion diagnostic approved by the Pharmaceuticals and Medical Devices Agency. In 2020, ArcherDX was acquired by Invitae Corporation where Joshua served as President of Oncology following the acquisition.

Daan is a trained internist / gastroenterologist with over 25 years of clinical practice. He served various roles including Department Chair and Professor of Gastroenterology and Hepatology at Leiden University Medical Center; Professor of Medicine at University of California Los Angeles (UCLA); President of the European Crohn’s and Colitis Organization (ECCO); Professor of Health Innovation and Applied Artificial Intelligence at the University of Leiden; and Founder and CEO of DEARhealth, a UCLA spin-off company offering AI-powered Care Pathways.

Daan completed his Ph.D. in biomarkers and experimental treatments in Inflammatory Bowel Diseases (IBD) and, having lectured around the world and authored over 280 peer-reviewed papers, he offers InterVenn deep scientific and clinical expertise in host immune responses, malignant transformation processes and biomarker development.

Dan is the Chief Data Officer at InterVenn, with over 15 years of experience mining the genome and proteome for biological and clinical insights. After joining in late 2017, his team was responsible for training, deploying, and publishing the world's first neural network for mass spectrometry peak selection and integration.

Prior to starting at InterVenn, Dan led analytical efforts for dozens of scientific publications in cancer, neurodegenerative disease, and cardiovascular health at the Mayo Clinic. He holds a Bachelor of Science degree in Mathematics from the University of Minnesota and a Master's in Applied Statistics from Penn State. His team continues development on advanced machine learning techniques for detecting, quantifying, and utilizing glycoproteins, in service of the ultimate goal: moving these novel biomarkers into clinical practice and improving patient outcomes.

A leader with over thirty years of experience building and managing teams at the intersection of the physical and computational sciences with medicine and biology. He possesses in-depth and working knowledge in strategic planning, clinical research and trials, operations, project management, technology transfer and business/partnership development. Andrew was the Chief Science Officer at Standard BioTools, Inc (formerly Fluidigm), and was the liaison and bridge to the research community, identifying opportunities to address unmet needs in human health. He also served as the Genomics Business Unit Leader and was responsible for Product Marketing and Product Management.

Andrew also was the Director of Strategic Scientific Initiatives and Partnerships at the Frederick National Laboratory for Cancer Research and held faculty positions in the Department of Cancer Biology at Thomas Jefferson University and the Department of Oncology at Georgetown University. Andrew oversaw the operation of the shared services for the Kimmel Cancer Center and his research focused on systems biology approaches and mass spectrometry to understanding mechanisms of resistance to treatment of breast cancer and biomarkers of response. He has published extensively and served on the editorial boards of Cancer Research and The American Journal of Pathology.

Pete is the Senior Vice President of Finance and Accounting at InterVenn, with 20 years of experience. Prior to InterVenn, Pete was previously the Vice President, Finance and Accounting at Genapsys, a sequencing technology firm that aimed to transform the human condition by building a scalable, affordable genomic sequencing ecosystem that supports research and diagnostics. Prior to Genapsys, he served as Corporate Controller for ArcherDx, a leading genomics analysis company that focused on developing industry-leading products and services for therapy optimization and cancer monitoring. Pete started his career at Deloitte. He holds a Master of Accounting Science degree, a Bachelor of Science degree in Finance and a Bachelor of Science degree in Accounting from the University of Illinois.

A seasoned executive with over two decades of experience spanning both the private and public sectors, Dana Moss, General Counsel, brings unparalleled expertise to InterVenn. Her background in compliance, business transactions, commercial litigation and government service has given her a deep understanding of navigating complex legal landscapes and driving organizational success. Dana has held multiple executive leadership roles at biotech and biopharma companies, including Director of Navidea Biopharmaceuticals, Chief Legal Officer & Corporate Secretary at Sequencing Health, Inc. and General Counsel & Corporate Secretary at Genapsys, Inc. Prior to that, Dana was a partner at Cooley LLP. Committed to shaping the trajectory of life science companies through strategic counsel and governance, Dana has spearheaded major initiatives in mergers and acquisitions, regulatory compliance, and intellectual property strategy, while also serving as a trusted advisor to management teams and boards of directors. Dana received her B.S. from the US Air Force Academy, a Master’s in Philosophy from the University of Texas at Austin, and her JD from the University of Maryland Francis King Carey School of Law.

Kim MacMartin-Moglia is the Vice President of Business Development at InterVenn, with over 25 years of experience in the medical diagnostics industry. During her tenure at InterVenn, Ms. MacMartin-Moglia has developed relationships with partner companies to enable the discovery of novel glycoproteomic biomarker signatures utilized for early diagnosis, disease prognosis and therapeutic response. In addition, she has developed a team of business development professionals to support the company's rapid growth and evolving business development needs.

Prior to InterVenn, Kim previously held the position of Director of Business Development at Inova Diagnostics/Werfen, an autoimmune focused IVD company and as the Director of Business Development at Prometheus Laboratories, a specialty CLIA reference laboratory focused on Gastroenterology/Oncology. She started her career at Quest Diagnostics working in the molecular genetics laboratory and after receiving her MBA, went on to work in sales and marketing roles in positions of increasing responsibility at Quest. She received her B.A. in Biochemistry and Cell Biology from UCSD and her MBA with an emphasis on Marketing and Finance from the University of San Diego.